Who
Colin Walsh
Director
Company insider
Files Form 4 as: Director, Attovia Therapeutics; Director, Elevation Oncology.
In numbers
- Trades disclosed
- 131
- Buys
- 4
- Sells
- 2
- Bought
- $41.1M
- Sold
- $9.0M
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 24 Jun 2021
- Last trade
- 6 Aug 2026
- Last filed
- 28 Aug 2026
Companies traded
Activity over time
1 Aug – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Aug 2026filed 28 Aug 2026 | ATTO Attovia TherapeuticsBiotechnology | SEC FORM 4 Code C | —1,957,134 at $0.00 | filing |
| 6 Aug 2026filed 28 Aug 2026 | ATTO Attovia TherapeuticsBiotechnology | SEC FORM 4 Code C | —478,498 at $0.00 | filing |
| 6 Aug 2026filed 28 Aug 2026 | ATTO Attovia TherapeuticsBiotechnology | SEC FORM 4 Bought | $8.5M500,000 at $17.00 | filing |
| 6 Aug 2026filed 28 Aug 2026 | ATTO Attovia Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —18,181,830 at $0.00 | filing |
| 6 Aug 2026filed 28 Aug 2026 | ATTO Attovia Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —4,445,275 at $0.00 | filing |
| 6 Aug 2026filed 28 Aug 2026 | ATTO Attovia Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —18,181,830 at $0.00 | filing |
| 6 Aug 2026filed 28 Aug 2026 | ATTO Attovia Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —4,445,275 at $0.00 | filing |
| 6 Aug 2026filed 28 Aug 2026 | ATTO Attovia TherapeuticsBiotechnology | SEC FORM 4 Code C | —1,957,134 at $0.00 | filing |
| 6 Aug 2026filed 28 Aug 2026 | ATTO Attovia TherapeuticsBiotechnology | SEC FORM 4 Code C | —478,498 at $0.00 | filing |
| 6 Aug 2026filed 28 Aug 2026 | ATTO Attovia TherapeuticsBiotechnology | SEC FORM 4 Bought | $8.5M500,000 at $17.00 | filing |
| 6 Aug 2026filed 13 Aug 2026 | ATTO Attovia TherapeuticsBiotechnology | SEC FORM 4 Code C | —1,957,134 at $0.00 | filing |
| 6 Aug 2026filed 13 Aug 2026 | ATTO Attovia TherapeuticsBiotechnology | SEC FORM 4 Code C | —478,498 at $0.00 | filing |
| 6 Aug 2026filed 13 Aug 2026 | ATTO Attovia TherapeuticsBiotechnology | SEC FORM 4 Bought | $8.5M500,000 at $17.00 | filing |
| 6 Aug 2026filed 13 Aug 2026 | ATTO Attovia Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —18,181,830 at $0.00 | filing |
| 6 Aug 2026filed 13 Aug 2026 | ATTO Attovia Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —4,445,275 at $0.00 | filing |
| 6 Aug 2026filed 13 Aug 2026 | ATTO Attovia Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —18,181,830 at $0.00 | filing |
| 6 Aug 2026filed 13 Aug 2026 | ATTO Attovia Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —4,445,275 at $0.00 | filing |
| 6 Aug 2026filed 13 Aug 2026 | ATTO Attovia TherapeuticsBiotechnology | SEC FORM 4 Code C | —1,957,134 at $0.00 | filing |
| 6 Aug 2026filed 13 Aug 2026 | ATTO Attovia TherapeuticsBiotechnology | SEC FORM 4 Code C | —478,498 at $0.00 | filing |
| 6 Aug 2026filed 13 Aug 2026 | ATTO Attovia TherapeuticsBiotechnology | SEC FORM 4 Bought | $8.5M500,000 at $17.00 | filing |
News
No headline names them, or the companies they trade most, lately.